Sun Pharma Q2 Profit Falls 36% on Acquisition Charges Despite Revenue Beat

Sun Pharmaceutical on October 30, 2026 reported Q2 FY27 revenue of ₹16,199 crore, up roughly 12% year over year. Consolidated net profit fell about 36% to roughly ₹1,989 crore. EBITDA was ₹4,743 crore, up 5%, while EBITDA margin narrowed to about 29.3% from about 31.3%. An exceptional charge of about ₹1,270 crore (Reuters: ₹12.69 billion) was tied largely to Organon acquisition costs and India labour-code provisions; adjusted net profit was ₹3,162 crore. US formulation sales fell 8.2% to $455 million. India sales rose 17.3% to ₹5,552 crore (34.5% of sales). Emerging Markets formulation sales were $350 million, up 7.6%; Rest of World $241 million, up 3.1%; global innovative medicines $356 million, up 6.9%. R&D spend was ₹778.4 crore, 4.8% of sales. Managing Director Kirti Ganorkar said: "Our performance during the quarter was driven by strong momentum in India, Emerging Markets and Rest of World. Among key developments, Ilumya is now approved in the U.S. for the treatment of adults with active psoriatic arthritis." Shares rose after the announcement. Rated coverage in the record is only from the right (CNBC TV18); no left- or center-rated headlines are listed. Outlets differ on exact profit rounding and on whether revenue/PAT met or missed their own estimates.